



For the Management of Uncontrolled T2DM

Sitahenz-E 10

Sitagliptin 100 mg + Empagliflozin 10 mg Tablets

Sitahenz-E 25

Sitagliptin 100 mg + Empagliflozin 25 mg Tablets

Sitahenz-E 10, 25

BACKGROUND:

In individuals with advanced Type 2 diabetes, combination therapy is often unavoidable to maintain glycaemic control. International consensus has recognized the need for combination therapy for glucose lowering in patients with a high HbA1c level and recommend combination therapy when the HbA1c level is >7.5% in the initial assessment. Complimentary mechanism of action and good tolerance profile of DPP-4 and SGLT2 inhibitors make them attractive treatment options for combination therapy with any of the existing glucose-lowering agents. Combination therapy of Empagliflozin and Sitagliptin results in sustained, rapid, and satisfactory glucose control without severe adverse events.

INDICATION:

As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.

MECHANISM OF ACTION:

Sitagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide to facilitate glucose regulation in response to a meal.

Empagliflozin inhibits SGLT2 and blocks reabsorption of filtered glucose in the kidney, increasing urinary glucose excretion and reducing blood glucose levels. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.

DOSAGE:

Sitahenz-E 10, 25: One tablet a day orally or as prescribed by the doctor.

References:

1. *Diabetes Obes Metab.* 2015 Mar 22;17(7):616–621.
2. *Diabetes Metab J* 2024;48:253–264



Scan for more
Prescribing Information

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2025 All rights reserved. La Renon Healthcare Private Limited